Case Study by LEO Pharma: IL22R a new target for treatment of Atopic Dermatitis (AD)

Time: 11:15 am
day: Day One


• Studying the mechanisms being trialled for systemic treatment of AD
• What is the pharmacological relevance of inhibiting IL22R for treatment of AD?
• Examining the preclinical skin models used to evaluate IL22R as a new target